By Fineline Cube 
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting a 5.8% year-on-year (YOY) increase in sales to USD23.743 billion. Net earnings rose by 18.2% YOY to USD5.537 billion. The company attributed this growth to strong operational performance and favorable foreign exchange results, leading to an increase in the full-year estimated reported sales guidance at the midpoint by USD2 billion, representing a 5.4% adjustment.
Business Segment Performance
By business segment, the Innovative Medicine division reported a 4.9% YOY increase in sales to USD15.202 billion. The MedTech business segment saw growth of 7.3%, reaching USD8.541 billion. Regionally, the U.S. market contributed significantly with a 7.8% growth to USD13.544 billion, while the international market grew by 3.2% to USD10.199 billion.
Pipeline Product Advancements
Johnson & Johnson’s pipeline products made several significant advancements in 2025Q2. Imaavy (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody (mAb), received FDA approval for the treatment of generalized myasthenia gravis (gMG). The Intravesical drug-releasing system TAR-200 has been granted priority review status for its New Drug Application (NDA). Additionally, the CAR-T cell therapy CARVYKTI (ciltacabtagene autoleucel) demonstrated long-term survival data in patients with relapsed or refractory multiple myeloma (RRMM), showing consistent progression-free survival (PFS) and overall survival (OS) benefits over five years. The clinical trial for OTTAVA, a general surgery robotic system, is also ongoing.-Fineline Info & Tech